Abstract PS15-02: A Phase Ⅰb Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage
Jiayu Wang(Nanjing University of Chinese Medicine), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Kathryn Stazzone, Manojkumar Bupathi(Rocky Mountain Cancer Centers), w. Jeffery Edenfield(Prisma Health), Hong Zong(First Affiliated Hospital of Zhengzhou University), Kunyan Li(Central South University), Tao Sun(Wuhan University), Yanxia Shi(Chinese Academy of Agricultural Sciences), Dejan Juric(Massachusetts General Hospital), Andrea L.M. Silber(Yale University), Ling Zhang(Hebei Medical University), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Yiding Chen(Second Affiliated Hospital of Zhejiang University), Zhe Shi(National University of Singapore), Yihong Zhang(Xihua University), Quchang Ouyang(Hunan Cancer Hospital), Kate Lathrop(The University of Texas MD Anderson Cancer Center), Yaolin Wang, Xu Wang(Xuzhou Medical College), Erika Hamilton(Sarah Cannon)
Cited by 1
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k
HER2-Low Breast Cancer: Pathological and Clinical Landscape
|Journal of Clinical Oncology|2020|801
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761